60% by 2030
Growth of radiotherapeutics is expected to continue and will represent 60 percent of the nuclear medicine market by 2030 (MEDraysintell Nuclear Medicine Edition 2017).
The radiopharmaceutical landscape is changing.
We are uniquely committed to nuclear medicine and making investments to support clinical trials of new radiopharmaceuticals that help advance patient care.
Therapeutic
The last few years have shown robust growth in radiotherapeutics, which now make up 12 percent of the total nuclear medicine market, increased from 4 percent in 2013. Growth of radiotherapeutics is expected to continue and will represent 40 percent of the nuclear medicine market by 2030 (MEDraysintell Nuclear Medicine Edition 2017). As the landscape of radiopharmaceuticals changes, Cardinal Health remains committed to providing our customers with reliable access to innovative therapeutic radiopharmaceuticals, helping advance patient care.
Our therapeutic radiopharmaceuticals
- Iodine I 131 iobenguane (Azedra)
- Iodine I 131 sodium iodide
- Radium Ra 223 dichloride injection (XOFIGO®)
- Samarium Sm 153 lexidronam
- Strontium Sr 89 chloride
- Yttrium Y 90 ibritumomab tiuxetan
